» Articles » PMID: 17665498

Is Full Bilateral Retroperitoneal Lymph Node Dissection Always Necessary for Postchemotherapy Residual Tumor?

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2007 Aug 1
PMID 17665498
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Traditionally, postchemotherapy (PC) surgery for metastatic nonseminomatous germ cell tumor (NSGCT) has used a full bilateral retroperitoneal lymph node dissection (RPLND) from the crus of the diaphragm to the bifurcation of the common iliac arteries, from ureter to ureter. With the primary landing zone well defined in low-volume retroperitoneal disease, the authors performed modified dissections in the PC setting in a select population; and, herein, they report disease outcome.

Methods: From 1991 to 2004, a retrospective review of the testicular cancer database at the authors' institution was performed to identify patients with NSGCT, normal serum tumor markers after cisplatin-based chemotherapy, and residual retroperitoneal tumor who underwent modified PC-RPLND. All patients had metastatic disease at initial presentation that was limited to the primary landing zone (left or right).

Results: One hundred patients were identified, including 43 who underwent a right modified template, 18 patients who underwent a left full modified template, and 39 patients who underwent a left modified template. Pathology revealed cancer in 2% of patients, teratoma in 62% of patients, and necrosis in 36% of patients. The 2- and 5-year disease-free survival rate was 95%, and the median follow-up was 31.9 months (range, 1-152 months). Four patients developed recurrent disease with a median time to recurrence of 8.25 months (range, 6-11 months). All recurrences were outside the boundaries of a full bilateral RPLND.

Conclusions: Selected patients at PC surgery can be managed with modified PC-RPLND.

Citing Articles

Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer.

McClintock G, Goolam A, Perera D, Downey R, Leslie S, Grimison P Asian J Urol. 2024; 11(1):121-127.

PMID: 38312811 PMC: 10837656. DOI: 10.1016/j.ajur.2022.03.010.


Male infertility and urological tumors: Pathogenesis and therapeutical implications.

Gulino G, Distante A, Akhundov A, Bassi P Urologia. 2023; 90(4):622-630.

PMID: 37491831 PMC: 10623618. DOI: 10.1177/03915603221146147.


Salvage Strategies for Management of Testicular Tumors.

Chatterjee S, Rawal S Indian J Surg Oncol. 2022; 8(3):389-396.

PMID: 36118409 PMC: 9478072. DOI: 10.1007/s13193-016-0614-1.


Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy.

Nicolai N, Nazzani S, Tesone A, Macchi A, Piva L, Salvioni R Tumori. 2022; 109(4):379-386.

PMID: 35915559 PMC: 10363949. DOI: 10.1177/03008916221112697.


Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility.

Fankhauser C, Afferi L, Stroup S, Rocco N, Olson K, Bagrodia A World J Urol. 2022; 40(6):1505-1512.

PMID: 35279732 DOI: 10.1007/s00345-022-03974-9.